Sangamo Therapeutics Stock Alpha and Beta Analysis
| SGMO Stock | USD 1.27 0.01 0.79% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Sangamo Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Sangamo Therapeutics over a specified time horizon. Remember, high Sangamo Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Sangamo Therapeutics' market risk premium analysis include:
Beta 2.24 | Alpha 0.0548 | Risk 10.29 | Sharpe Ratio (0.06) | Expected Return (0.58) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Sangamo |
Sangamo Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Sangamo Therapeutics market risk premium is the additional return an investor will receive from holding Sangamo Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Sangamo Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Sangamo Therapeutics' performance over market.| α | 0.05 | β | 2.24 |
Sangamo Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Sangamo Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Sangamo Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Sangamo Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Sangamo Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Sangamo Therapeutics shares will generate the highest return on investment. By understating and applying Sangamo Therapeutics stock market price indicators, traders can identify Sangamo Therapeutics position entry and exit signals to maximize returns.
Sangamo Therapeutics Return and Market Media
The median price of Sangamo Therapeutics for the period between Sat, Nov 9, 2024 and Fri, Feb 7, 2025 is 1.94 with a coefficient of variation of 31.43. The daily time series for the period is distributed with a sample standard deviation of 0.57, arithmetic mean of 1.83, and mean deviation of 0.5. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Sangamo Therapeutics Inc Q3 2024 Earnings Call Highlights Strategic Advances and ... | 11/13/2024 |
2 | Disposition of 7473 shares by Macrae Sandy of Sangamo Therapeutics at 1.88 subject to Rule 16b-3 | 11/22/2024 |
3 | Disposition of 10642 shares by Macrae Sandy of Sangamo Therapeutics at 1.94 subject to Rule 16b-3 | 11/25/2024 |
4 | Disposition of 5474 shares by Duraibabu Prathyusha of Sangamo Therapeutics at 1.13 subject to Rule 16b-3 | 12/13/2024 |
5 | Futures Rebound After Powells Hawkish Pivot Plunge | 12/19/2024 |
6 | TD Cowen disappointed Pfizer ended Sangamo collaboration SGMOPFEBMRN | 12/31/2024 |
7 | Sangamo Therapeutics, Inc. Investors Who Lost Money Contact Law Offices of Howard G. Smith About Securities Fraud Investigation | 01/02/2025 |
8 | Pharma Stock Roundup PFE Ends Hemophilia Deal With SGMO More | 01/03/2025 |
9 | Sangamo Therapeutics Inc. This Small-Cap Stock Is Poised To Outperform in 2025 | 01/07/2025 |
10 | Bronstein, Gewirtz Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. and Encourages Shareholders to Learn More About the Investigation... | 01/14/2025 |
11 | Disposition of 412584 shares by Macrae Sandy of Sangamo Therapeutics at 1.15 subject to Rule 16b-3 | 01/22/2025 |
12 | Sangamo Therapeutics Price Target Cut to 5.00 by Analysts at Truist Financial | 01/24/2025 |
13 | Pfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 Guidance | 02/04/2025 |
14 | Sangamo reports updated data for gene therapy candidate ST-920 | 02/06/2025 |
About Sangamo Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Sangamo or other stocks. Alpha measures the amount that position in Sangamo Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | Days Sales Outstanding | 14.67 | 2.75 | 3.16 | 3.0 | PTB Ratio | 1.64 | 1.14 | 1.31 | 1.25 |
Sangamo Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Sangamo Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Sangamo Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Sangamo Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Sangamo Therapeutics. Please utilize our Beneish M Score to check the likelihood of Sangamo Therapeutics' management manipulating its earnings.
| 28th of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Sangamo Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Sangamo Therapeutics Backtesting, Sangamo Therapeutics Valuation, Sangamo Therapeutics Correlation, Sangamo Therapeutics Hype Analysis, Sangamo Therapeutics Volatility, Sangamo Therapeutics History and analyze Sangamo Therapeutics Performance. To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Sangamo Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.